Loteprednol etabonate mucosal penetrating particle: Phase II started

Kala began the double-blind, vehicle-controlled, U.S. Phase II KPI-121-C-003 trial to evaluate 0.25% LE-MPP eye drops given 4 times daily for 28 days in about 150 patients with inflammatory meibomian ...